Webcast CME

Series Activities

Series Menu

Biologic Therapies Summit IX: Immune-based Inflammatory Diseases Through the Lens of COVID-19 and Specific Questions in Vasculitis Treatment

How does the treatment of Behçet’s disease differ based on disease manifestations?

Print this Content

Release date: July 12, 2021
Expiration date: July 12, 2023

Estimated Time of Completion: 30 minutes

Description

In the Biologic Therapies Summit IX: Immune-based Inflammatory Diseases Through the Lens of COVID-19 and Specific Questions in Vasculitis Treatment online series, an international, multi-disciplinary faculty of experts focuses on immune-mediated disease, with a focus on new perspectives due to COVID-19. Additionally, there is a focus on vasculitis and factors that influence the selection of treatments for vasculitis disorders.

How does the treatment of Behçet’s disease differ based on disease manifestations? webcast highlights disease course and treatment response between organ manifestations in Behçet’s syndrome.

Learning Objectives

  1. Identify the differences in the disease course and treatment response between organ manifestations in Behçet’s syndrome.
  2. Plan the treatment of patients with Behçet’s syndrome according to the organs that are involved, disease severity and risk factors.
  3. Identify modalities to monitor patients with different types of organ involvement during follow-up.

Target Audience

The online series is designed for rheumatologists, dermatologists, infectious disease physicians, allergists, clinical immunologists, as well as specialists in integrative medicine, preventive medicine, wellness, primary care, and other health care professionals caring for patients with vasculitis and immune-mediated inflammatory diseases.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.


American Board of Internal Medicine MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Your credit will be reported to the ABIM within 30 days of claiming credit.

Activity Director and Faculty

Activity Directors

Cassandra Calabrese, DO
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Carol Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Gülen Hatemi, MD
Professor of Medicine
Istanbul University – Cerrahpaşa
Istanbul, Turkey

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. 

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Leonard H. Calabrese, DO Abbvie Pharmaceuticals, BMS, Genentech/Roche, Janssen, Novartis Consulting
Teaching and Speaking
Astra Zeneca, Crescendo Teaching and Speaking
GSK, Regeneron, Sanofi Aventis, UCB Consulting
Gulen Hatemi, MD Amgen, UCB, Inc. Consulting
Teaching and Speaking
Abbvie Pharmaceuticals, MSD, Novartis Pharmaceuticals Teachingand Speaking
Bayer Schering Pharma Ag, Johnson & Johnson Consulting
Celgene Corporation Consulting
Research / Independent Contractor
Teaching and Speaking
Silk Road Medical Research / Independent Contractor
M. Elaine Husni, MD Abbvie Pharmaceuticals, Amgen, Bristol-Myers Squibb Co., Janssen, Lilly, Regeneron Consulting
Membership on advisory committee or review panels
Genenetch, UCB, Inc. Consulting
Novartis Pharmaceuticals Consulting
Membership on advisory committee or review panels
Teaching and Speaking
Pfizer, Inc. Membership on advisory committee or review panels
WebMD Consulting
Teaching and Speaking
Carol Langford, MD Abbvie Pharmaceuticals Non-paid consultant for research
Astrazeneca Pharmaceuticals, Bristol-Myers Squibb Co. Non-paid consultant for research
Clinical trial funding support
Chemocentryx, Genenetch, GlaxoSmithKline Clinical trial funding support

The following faculty has indicated she has no relationship which, in the context of her presentation(s), could be perceived as a potential conflict of interest:

Cassandra Calabrese, DO

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:

AbbVie, Inc.
Bristol-Myers Squibb Company
Genentech USA, Inc.
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
UCB, Inc.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Live activity from:

AbbVie, Inc.
Bristol-Myers Squibb Company
Genentech USA, Inc.
Janssen Scientific Affairs, LLC
Lilly USA, LLC
Novartis Pharmaceuticals Corporation
Pfizer Inc.
UCB, Inc.

 


This CME activity was produced by the Cleveland Clinic Center for Continuing Education
and Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology.